Skip to main content

Table 1 Patient characteristics at baseline

From: The efficacy of human epidermal growth factor receptor 2 (HER2) blockade switching mode in refractory patients with HER2-positive metastatic breast cancer: a phase II, multicenter, single-arm study (SYSUCC-005)

Characteristics

Mean or Case Number (%)

Age (years) at diagnosis

  Mean

47.3

  Range

24–75

Menopausal status at diagnosis

  Premenopausal

75 (47.2)

  Postmenopausal

84 (52.8)

HR status

  Negative

105 (66.0)

  Positive

54 (34.0)

Number of metastatic sites

  < 2

91 (57.2)

  ≥ 2

68 (42.8)

Brain metastases

  Yes

37 (23.3)

  No

122 (76.7)

Visceral metastasesa

  Yes

101 (63.5)

  No

58 (36.5)

Prior trastuzumab treatment

  Adjuvant setting only

52 (32.7)

  Adjuvant and metastatic setting

25 (15.7)

  Metastatic setting only

82 (51.6)

Duration of previous trastuzumab

  < 6 months

71 (44.7)

  ≥ 6 months

88 (55.3)

Chemotherapy regimens with Lapatinib

  Capecitabine

108 (67.9)

  Vinorelbine

51 (32.1)

  1. aMetastases in lung/liver
  2. Abbreviation: HR hormone Receptor